Coronary artery embolism is a rare but serious cardiovascular condition characterized by the obstruction of coronary arteries, which supply blood to the heart muscle, by emboli or clots that originate from distant sites in the circulatory system. Unlike traditional coronary artery disease, where plaque buildup is the primary cause of blockages, embolisms in coronary arteries often result from the migration of blood clots or other debris. This can lead to a sudden disruption of blood flow to the heart, causing a heart attack. The symptoms of coronary artery embolism are similar to those of a typical heart attack and may include chest pain, shortness of breath, and fatigue. Due to its uncommon nature, diagnosis can be challenging, requiring a combination of clinical evaluation, imaging studies, and cardiac catheterization. Prompt recognition and intervention are crucial for managing coronary artery embolism, typically involving anticoagulant therapy and, in some cases, mechanical interventions such as catheter-based procedures. As research continues to unfold, a better understanding of this condition will contribute to improved diagnostic tools and treatment strategies.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India